157 related articles for article (PubMed ID: 14679399)
1. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
[TBL] [Abstract][Full Text] [Related]
2. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
3. Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.
Luo S; Cassidy W; Jeffers L; Reddy KR; Bruno C; Howell CD
Clin Gastroenterol Hepatol; 2005 May; 3(5):499-506. PubMed ID: 15880320
[TBL] [Abstract][Full Text] [Related]
4. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
Abe H; Hayes CN; Ochi H; Maekawa T; Tsuge M; Miki D; Mitsui F; Hiraga N; Imamura M; Takahashi S; Kubo M; Nakamura Y; Chayama K
J Hepatol; 2011 Jun; 54(6):1094-101. PubMed ID: 21145800
[TBL] [Abstract][Full Text] [Related]
5. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
J Hepatol; 2003 Sep; 39(3):421-7. PubMed ID: 12927929
[TBL] [Abstract][Full Text] [Related]
6. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha (IFN alpha) daily dose versus IFN alpha plus ribavirin for treatment-naive chronic hepatitis c patients infected by genotype 1b.
Scotto G; Campanozzi F; D'Adduzio A; Grimaldi M; Fazio V
BioDrugs; 2003; 17(4):281-6. PubMed ID: 12899645
[TBL] [Abstract][Full Text] [Related]
10. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
[TBL] [Abstract][Full Text] [Related]
11. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Kim KI; Sasase N; Taniguchi M; Mita K; Kinoshita K; Togitani T; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Muramoto Y; Kim SR; Nabeshima S; Ishii F; Tanaka K; Hayashi Y
Int J Clin Pharmacol Res; 2005; 25(2):71-6. PubMed ID: 16060397
[TBL] [Abstract][Full Text] [Related]
13. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.
Feld JJ; Modi AA; El-Diwany R; Rotman Y; Thomas E; Ahlenstiel G; Titerence R; Koh C; Cherepanov V; Heller T; Ghany MG; Park Y; Hoofnagle JH; Liang TJ
Gastroenterology; 2011 Mar; 140(3):830-9. PubMed ID: 20854821
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
Di Bisceglie AM; Fan X; Chambers T; Strinko J
J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
[TBL] [Abstract][Full Text] [Related]
15. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
16. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
17. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
[TBL] [Abstract][Full Text] [Related]
19. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta.
Shiratori Y; Perelson AS; Weinberger L; Imazeki F; Yokosuka O; Nakata R; Ihori M; Hirota K; Ono N; Kuroda H; Motojima T; Nishigaki M; Omata M
J Hepatol; 2000 Aug; 33(2):313-22. PubMed ID: 10952250
[TBL] [Abstract][Full Text] [Related]
20. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
